Semaglutide's mechanism of action: what it does inside your body

Imagine your body has just received a meal, then imagine that signal running on a seven-day loop

GLP-1 is one of several hormones your gut secretes when food arrives. In someone without medical intervention, the spike is brief, the hormone is degraded within minutes by an enzyme called DPP-4. Semaglutide is engineered to look enough like GLP-1 to activate the same receptors, but with a molecular modification and an albumin-binding fatty acid chain that protects it from rapid breakdown. The result is a molecule with a half-life of around seven days. That single weekly injection, detailed on our Wegovy overview page, keeps receptor activation at a steady, sustained level that a natural post-meal GLP-1 surge simply cannot match.

One misconception worth setting aside gently: many people assume semaglutide speeds up metabolism or directly targets fat cells. It does neither. What changes is the input side, how hungry you feel, and how long you feel full. The downstream effect is that most people eat substantially less without having to consciously fight every meal.

The hypothalamus, the brain region most involved in hunger and satiety signalling, has GLP-1 receptors. When semaglutide reaches them, the brain's hunger tone is turned down. Separately, semaglutide slows the rate at which food moves from the stomach into the small intestine (a process called gastric emptying) which prolongs the physical sensation of fullness after a meal. The two effects compound each other. You can read more about how semaglutide's mechanism of action works across these different receptor sites on our dedicated page explaining it at a molecular level.

What the pancreas and blood sugar have to do with it

GLP-1 receptors in the pancreas play a role in insulin secretion. When blood glucose rises after eating, semaglutide's activation of those receptors encourages the pancreas to release insulin and suppresses glucagon (the hormone that raises blood sugar). Critically, this only happens when glucose is actually elevated, a property described as glucose-dependent. That mechanism is one reason the risk of hypoglycaemia (dangerously low blood sugar) is low in people who do not have type 2 diabetes, compared with some older diabetes medicines.

This dual action on appetite and blood sugar is why semaglutide holds a UK licence both for weight management (as Wegovy) and for type 2 diabetes (as Ozempic). The doses differ, the titration schedules differ, and the conditions they are licensed for are distinct. Ozempic is licensed for type 2 diabetes management (not for weight loss) and the two should not be conflated. Our semaglutide mode of action page covers how the same molecule behaves differently at different doses.

For weight management, the STEP 1 trial (published in the New England Journal of Medicine) found that adults treated with semaglutide 2.4mg weekly achieved an average body-weight reduction of around 15% over 68 weeks alongside lifestyle support, compared with around 2.4% with placebo. That result is a downstream consequence of the mechanism described above: not a direct pharmacological fat-reduction, but a sustained shift in the appetite and satiety signals that govern how much a person eats day to day.

From mechanism to practice: what this means if you are considering treatment

Understanding the mechanism matters because it shapes realistic expectations. Semaglutide does not override willpower, it changes the neurochemical environment in which choices are made. Most people report that food simply becomes less compelling, and that they feel satisfied with smaller portions. Some notice the effect clearly within the first few weeks; others take longer to feel a meaningful shift, particularly at the lower starting doses used during titration.

The titration schedule (starting low and increasing gradually) exists precisely because of the GI side-effect profile that follows from slowing gastric emptying. Nausea, loose stools and indigestion are common early on, particularly after a dose increase, and are generally mild-to-moderate and transient as the body adjusts. The semaglutide onset of action page covers the typical timeline in more detail.

Because semaglutide affects gastric emptying, it can also influence how quickly other oral medicines are absorbed, a practical consideration your prescriber will factor in. For women using oral contraceptives while taking tirzepatide (a different, dual-agonist medicine also available at nume, sorry, at our clinic), specific guidance applies; a similar caution for semaglutide oral absorption is worth raising at consultation. If you are weighing up which licensed treatment suits your situation, our weight loss treatment overview sets out the options clearly, including details on our 10ml semaglutide supply format for those who want to understand exactly what they would be prescribed. A prescriber (not an algorithm) will review your medical history and make that call. If you are ready to take that step, check your eligibility with our clinical team.